# **CURRICULUM VITAE**

## Gavin Rumbaugh, PhD

Department of Neuroscience The Scripps Research Institute 130 Scripps Way, #3C2 Jupiter, FL 33458 (561) 228-3461 grumbaug@scripps.edu

## **EDUCATION**

**Degree:** BS *(Cum Laude)*, 1996 Westminster College, New Wilmington, PA, USA Department of Biology

**Degree:** PhD, 2000 Georgetown University School of Medicine, Washington DC Departments of Pharmacology and Physiology/Biophysics (Advisor: Stefano Vicini, PhD)

#### Postdoctoral Fellowship: 2000-2007

Department of Neuroscience and the Howard Hughes Medical Institute; The Johns Hopkins University School of Medicine, (Advisor: Richard L. Huganir)

#### ACADEMIC POSITIONS

•	2007-2009	Assistant Professor, Department of Neurobiology; The University of Alabama at Birmingham, (UAB) School of Medicine; 2007-2009
•	2010-2012	Assistant Professor, Department of Neuroscience; The Scripps Research Institute, Jupiter, FL
•	2012-2014	Associate Professor, Department of Neuroscience; The Scripps Research Institute, Jupiter, FL
•	2014-2019	<i>Tenured Associate Professor,</i> Department of Neuroscience, The Scripps Research Institute, Jupiter, FL
٠	2019-	Professor, Department of Neuroscience, The Scripps Research Institute, Jupiter, FL

#### OTHER POSITIONS

• 2019- Paid Consultant, Stoke Therapeutics, Bedford, MA

#### HONORS AND AWARDS

- NIH R01 Award (NIDA; New Grant), 2019-2024
- NIH R01 Award (NINDS; New Grant), 2019-2024
- NIH R01 Award (NIMH; Competitive Renewal), 2018-2023
- NIH R01 Award (NIMH; New Grant), 2017-2020
- NIH R13 Conference Award (NINDS; New Grant), 2016
- NIH R21 Award (NIMH; New Grant), 2016-2018
- Kavli Fellow, 2015-2019

- NIH R01 Award (NIMH; New Grant), 2015-2020
- NIH R01 Award (NINDS; Competitive Renewal), 2014-2018
- NIH/NINDS R21/R33 Phased Innovation Award, 2013-2017
- Faculty of 1000 Selection (Griggs et. al.), 2013
- Faculty of 1000 Selection (Clement et. al.), 2012
- NIH R01 Award (NIMH; New Grant), 2012-2017
- Faculty of 1000 Selection (Kilgore et. al.), 2010
- Faculty of 1000 Selection (Miller et. al.), 2010
- American College of Neuropsychopharmacology (ACNP) Faculty Research Fellow, 2009-2011
- NARSAD Young Investigator Award, 2009-2010
- NIH R01 Award (NINDS; New Grant), 2009-2014
- NIH R03 Award (NICHD; New Grant), 2009-2011
- Faculty of 1000 Selection (Heine et. al.), 2008
- Alabama Health Services Foundation Scholar, 2007
- Faculty of 1000 Selection (Shepherd, Rumbaugh et. al.), 2006
- Faculty of 1000 Selection (Lee et. al.), 2003
- National Research Scholar Award (NRSA: F32 NS043071-03; NINDS), 2002-2005
- NCAA/NAIA Academic All-American (Men's Basketball), Westminster College, 1996
- Westminster College student-athlete of the year, 1996

## INVITED TALKS

## National

- (2005) The Johns Hopkins University School of Medicine, Department of Neuroscience, Baltimore, MD
- (2005) The Pennsylvania State University, Dept. of Biology/Huck Institute, State College, PA
- (2005) The Chicago School of Medicine, Dept. of Cellular and Molecular Pharmacology
- (2006) NYU School of Medicine, Skirball Institute, New York, New York
- (2006) The University of Texas at Austin, Department of Neurobiology and CLM, Austin, TX
- (2006) The University of Alabama Birmingham, Department of Neurobiology, Birmingham, AL
- (2007) Molecular and Cellular Cognition Society: Annual Symposium, San Diego, CA
- (2009) 48<sup>th</sup> Annual Meeting of The American College of Neuropsychopharmacology (ACNP), Hollywood, FL
- (2009) Tulane University, Seminar: Department of Cell and Molecular Biology, New Orleans, LA
- (2009) McKnight Brain Institute Symposium, Hoover, AL
- (2010) 49<sup>th</sup> Annual Meeting of The American College of Neuropsychopharmacology (ACNP), Miami Beach, FL
- (2010) Florida Atlantic University, Department of Neuroscience, Boca Raton, FL
- (2010) Max Planck Society Symposium, Boca Raton, FL
- (2010) 34<sup>th</sup> Annual Neurobiology of Learning and Memory Conference, Park City, Utah
- (2011) 50<sup>th</sup> Annual Meeting of The American College of Neuropsychopharmacology (ACNP), Kona, HI
- (2011) Harvard Medical School, Seminar: Dept. of Neurology, Massachusetts General Hospital, Boston, MA
- (2011) The Repligen Corporation, Clinical Pharmacology Division, Waltham, MA
- (2011) Biogen Idec, Neuroscience Discovery Division, Cambridge, MA

- (2011) University of California (Irvine), Seminar: Department of Pharmacology, Irvine, CA
- (2012) Northwestern University, Seminar: Feinberg School of Medicine, Department of Physiology, Chicago, IL
- (2013) Harvard Medical School, Seminar: Department of Psychiatry, McLean Hospital, Waltham, MA
- (2014) International Epilepsy Symposium, Newport Beach, CA
- (2014) Frontiers of Biomedical Research Symposium, Indian Wells, CA
- (2015) 25<sup>TH</sup> Neuropharmacology Conference: Synaptopathy From Biology to Therapy, Chicago, IL
- (2015) Agility Clinical, Carlsbad, CA
- (2016) 28<sup>th</sup> Annual Winter Conference on Neural Plasticity, Maui, HI
- (2016) US-Japan Meeting on Synapse Biology, Baltimore, MD
- (2016) Lurie Distinguished Endowed Lectureship, University of Cincinnati, Seminar: Department of Psychiatry and Behavioral Neuroscience, Cincinnati, OH
- (2017) Duke University, Seminar: Department of Cell and Molecular Biology, Duram, NC
- (2017) University of Texas, Southwestern Medical Center, Seminar: Department of Neuroscience, Dallas, TX
- (2017) The 5<sup>th</sup> Annual Molecular Psychiatry Meeting, San Francisco, CA
- (2017) Michigan State University, Mall Family Endowed Lecture, Department of Pediatrics, Grand Rapids/East Lansing, MI
- (2018) Children's National Hospital, Seminar: Neuroscience Research Center, Washington, DC
- (2018) 2<sup>nd</sup> International SYNGAP1 Conference: From Biology to Therapies
- (2019) Department of Psychiatry, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA
- (2019) 6th International RASopathies Symposium: Precision Medicine From Promise to Practice, Baltimore, MD
- (2020) Center for Autism, Feinberg School of Medicine, Northwestern University, Chicago, Il
- (2020) Stoke Therapeutics, Bedford, MA
- (2020) 3<sup>rd</sup> International SYNGAP1 Conference, Bethesda, MD

## International

- (2010) Italian National Research Council (CNR), Institute for Neurosciences, Rome, Italy
- (2011) 31<sup>st</sup> Blankenese Conference; Nucleo-Synaptic Cross-Talk in Nerve Cells, Blankenese, Germany
- (2011) University of Hamburg, Center for Molecular Neurobiology, Hamburg, Germany
- (2012) Advanced School on Membrane Biology; Montevideo, Uruguay
- (2012) International Society for Neurochemistry: 5th Special Conference; Dendritic Spine Biology, Buenos Aires, Argentina
- (2013) International Society for Neurochemistry Satellite Meeting on Synapse Biology
- (2014) Molecular Physiology of the Synapse Laboratory, Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spain
- (2014) Center for Neuroregeneration, The University of Edinburgh, Edinburgh, UK
- (2015) Kavli Frontiers of Science Symposium (Co-sponsored by the National Academy of Science), Jeju Island, South Korea
- (2015) Center for Synaptic Brain Dysfunctions and Institute for Basic Science (IBS), Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea
- (2015) Advanced School for the International Society for Neurochemistry: Synaptopathies: synaptic molecules with clinical implications, Fitzroy Island, Australia

- (2015) International Society of Neurochemistry (ISN) Biennial Meeting, Cairns, Australia
- (2016) NCCR Conference, The Neurobiology of Mental Health, Geneva, Switzerland
- (2018) Winter Conference on Brain Research, Session Chair and Panel Speaker, Whistler, Canada
- (2018) Keynote Address: Genetic Epilepsy Team Australia (GETA) Annual Meeting; Melbourne, Australia
- (2018) Gordon Research Conference; Fragile X and Autism Spectrum Disorders; Barga, Italy
- (2019) US-Japan Meeting on Synapse Biology, Tokyo, Japan
- (2019) Korea Advanced Institute of Science and Technology (KAIST), Center for Synaptic Dysfunctions, Daejeon, South Korea
- (2020) Molecular and Cellular Cognition Society (MCCS) Workshop, Fiji
- (2020) Symposium on SYNGAP1 and Related Neurodevelopmental Disorders, Vienna, Austria
- (2020) Wellcome India Alliance-EMBO Conference on Cellular and Molecular Mechanisms of Neurodevelopmental Disorders, Bangalore, India
- (2020) SynGO Consortium: Synaptopothies, Baeza, Spain

## ORGANIZATIONAL DUTIES

- (2012) Scientific Advisory Board: International Society for Neurochemistry: 5th Special Conference; Dendritic Spine Biology. Buenos Aires, Argentina
  - Provided thematic input into the choice of sessions and helped invite speakers, including the plenary speaker.
- (2013) Meeting Organizer: International Society for Neurochemistry Satellite Meeting on Synapse Biology, Playa Del Carmen, Mexico.
  - With a budget of ~30,000 USD, I organized a four-day symposium with 25 speakers that focused on the role of synapse dysfunction in various brain diseases.
  - Executed all aspects of the meeting, including scouting of locations, logistics and creations of the symposium program
- (2016-2017) Member of Organizing Committee for the 3<sup>rd</sup> Korean-American Kavli Frontiers of Science Symposium
  - Panel of (10) Kavli Fellows were charged with identifying cutting-edge topics in Biology, Neuroscience, Physics, Engineering, Computer Science and Climate Science/Geology.
  - Personally invited speakers for the Neurobiology session of the Meeting, *"Neural activity during decision making"*.
  - Meeting will be held in Orange County, CA in the summer of 2017
- (2016) Meeting Organizer: First International *SYNGAP1* (MRD5) Conference, Texas Children's Hospital, Houston, TX.
  - I co-organized a Stakeholder meeting (Physicians, Biologists and Patient Advocacy Groups) that aimed to find a way forward to accelerate treatments for a rare genetic brain disorder.
  - My role was to select and then invite internationally recognized speakers (~22) for a two-day symposium, which focused on the clinical phenotype of the disorder, the biology influenced by the Syngap1 gene, and strategies to evaluate repurposed drugs for treatments of affected individuals.
  - PI on the NIH R13 application that funded a portion of the meeting.
- (2018) Meeting Organizer: Second International *SYNGAP1* (MRD5) Conference, The Scripps Research Institute, Jupiter, FL. To be held in the *Fall of 2018*

- (2018) Session Organizer and Session Chair: Postsynaptic Mechanisms Regulating the Assembly and Stability of Neural Circuits Relevant to Neuropsychiatric Disorders. Winter Conference on Brain Research, Whistler, BC
- (2019) Co-Chair; Organizing Committee for 4<sup>th</sup> Korean-American Kavli Frontiers of Science Symposium; To be Held in Inchon, South Korea in June 2019

## NIH STUDY SECTIONS

- (2013) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders
  - Reviewed grant applications for three high priority Program Announcements issued by the National Institute for Mental Health (NIMH).
- (2014) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders (February)
  - Reviewed grant applications for three high priority Program Announcements issued by the National Institute for Mental Health (NIMH).
- (2014) Brain Canada; Multi-investigator Initiative
  - o Review Board
- (2014) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders (November)
- (2015) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders
- (2015) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders
- (2015) NIH Special Emphasis Panel [ZRG1 MDCN-P(57)]: Molecular and Cellular Substrates of Complex Brain Disorders
- (2016) NIH Special Emphasis Panel [ZRG1 BDCN.W (03)]
- (2016) NIH Special Emphasis Panel [ZRG1 IFCN-T 02 M]
- (2016) NIH Review Panel: Molecular Neurogenetics (MNG) Study Section (Ad Hoc)
- (2017) NIH Special Emphasis Panel [ZRG1 BDCN-W (90)]
- (2017) NIH Review Panel: Molecular Neurogenetics (MNG) Study Section (Ad Hoc)
- (2018) NIH Special Emphasis Panel: ZRG1 BDCN-W (05)
- (2019) Invited Reviewer: 2019 NIH Director's Pioneer Award Program
- (2019) Invited reviewer: Special Emphasis Panel for RFA-TR-18-020: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
- (2019) Invited Reviewer: Special Emphasis Panel for <u>PAR 17-179/176</u> (U01), From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry.

## EDITORIAL AND SCIENCTIFIC ADVISORY BOARDS

- (2015-) Scientific Advisor: Bridge-The-Gap SYNGAP Education and Research Foundation
  - Provide expertise with respect to advances in *Syngap1* biology and the potential for therapeutic development for *SYNGAP1*-related brain disorders
- (2017-) Editorial Board Member: *Molecular Neuropsychiatry Journal,* Karger Publishing
- (2019-) Paid Consultant; Stoke Therapeutics, Bedford, MA

## GRADUATE STUDENT AND POST-DOCTORAL TRAINING

#### Current

- Graduate Students
  - o Murat Klinic, BS
- Post-doctoral Fellows
  - Sheldon Michaelson, PhD
  - o Nerea Llamosas, PhD
  - o Thomas Cresson
  - o Thomas Vaissiere
  - o Vineet Aurora

#### Past

- Graduate Students
  - o Maria Dolores Rubio
    - Mentored by Dr. Rumbaugh from 2008-2011
    - Became Resident in Psychiatry, McLean Hospital, Harvard Medical School (2013-2017)
    - Board Certified Psychiatrist in private practice (SF Bay Area)
  - $\circ~$  Cristin F. Gavin Graduation Date November 2012
    - Mentored by Dr. Rumbaugh from 2008-2012
    - Current Position: Assistant Professor; UAB
  - Mark Kilgore (co-mentored with David Sweatt, PhD)
    - Mentored by Dr. Rumbaugh from 2008-2013
    - Current Position: Patent Law Program; Birmingham Southern University
  - Antoine Almonte (co-mentored with David Sweatt, PhD)
    - Mentored by Dr. Rumbaugh from 2008-2013
    - Postdoctoral Fellow; UNC
- Post-doctoral Fellows
  - Xiaochuan Guo, MD, PhD
    - Graduate training at UAB
    - Member of Rumbaugh Lab from 2007-2010
    - Became Resident in Anesthesia at SUNY Downstate (2010-2014)
    - Current Position: Anesthesiologist with Emcare, Milford, CT
  - James Chelliah Clement, PhD
    - Graduate training at University of Bristol, UK
    - Member of Rumbaugh Lab from 2010-2013
    - Current Position: PI/Assistant Professor, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore, India
  - o Emin Ozkan, PhD
    - Graduate training at UT Southwestern
    - Member of Rumbaugh Lab from 2011-2017
    - Current Position:
  - Massimilliano Aceti, PhD
    - Graduate training at University of Rome
    - Member of Rumbaugh Lab from 2011-2017

 Current Position: Staff Scientist, Department of Drug Discovery, Moffitt Cancer Center, Tampa, FL

## SERVICE TO INSTITUTE/UNIVERSITY/GRADUATE SCHOOL

#### 1. Philanthropy and community participation

- Speaker; Children Services Council of Palm Beach County, 2014
- Speaker; Science of Health, Palm Beach, Florida, 2012
- Speaker, Science of Health, Vero Beach, Florida, 2012
- Speaker; Front Lines of Hope, TSRI-Florida, 2012
- Speaker; Mental Health Society of Palm Beach, 2011
- Speaker; "Lunch and Learn" Series; TSRI-Florida, 2010
- Speaker, BioFlorida Meeting, TSRI-Florida, 2010

#### 2. Teaching and Course Development

- Lecturer; Neuroscience Core Curriculum; UAB Graduate School, 2008-2010
  2-4 lectures per year + critical reading component; 10-20 contact hours
- Co-Course Director; Learning and Memory; TSRI Kellogg School, 2011-2012
  - o 10 contact hours
- Lecturer; Current topics in Neural Circuit Plasticity, TSRI Kellogg School, 2014-2016
- 8 contact hours

### 3. Committees (thesis committees; search committees;)

- Institutional Committees
  - TSRI-Florida Graduate School Theme Committee; 2010-2012
  - TSRI-Florida Seminar Series Committee; 2010-2012
  - Max Planck Florida Institute IACUC Committee; 2011-2012
  - Kellogg School Graduate Admission Committee (2015-2017)
- Graduate School Thesis Committees
  - University of Alabama, Birmingham
    - Antoine Almonte, Dept. of Neurobiology; 2008-2012
    - Brandon Walters, Dept. of Neurobiology; 2008-2010
    - Laura Hobbs, Dept. of Psychology; 2008-2010
    - Faraz Sultan, Dept. of Neurobiology; 2008-2010
    - John Hammond, Dept. of Psychiatry; 2008-2010
    - Adam Funk, Dept. of Psychiatry; 2008-2010
  - TSRI Kellogg School
    - Wesley Dang (Mayford Lab), Department of Neuroscience, 2014-
    - Andre Sousa (Mayford Lab), Department of Neuroscience, 2014-
    - Nadine Jospeh (Miller Lab), Department of Metabolism and Ageing, 2015-2017
    - Murat Klinic (Rumbaugh Lab), Department of Neuroscience, 2015-
    - Min Huang (Maximov Lab), Department of Neuroscience, 2016-
    - Jingyi Chen (Stowers Lab), Department of Neuroscience, 2017-
- Faculty Search Committee
  - University of Alabama, Birmingham
    - Assistant Professor of Neurobiology Search; 2009

#### **PUBLICATIONS**

**1.** Summary of Research Accomplishments (Search terms: Rumbaugh G or Rumbaugh GR, 1999-present):

Sum of Times Cited: h-index:	>4000 31
Number of Articles with >100 citations:	13
Number of Articles with >200 citations:	5
Number or Articles with >300 citations:	4
Number or Articles with >400 citations:	3
Number of F1000 Prime Articles:	7
Number of Cover articles:	4

## 2. Publications

- 1. <u>Rumbaugh G</u>, Vicini S. (1999) Distinct synaptic and extrasynaptic NMDA receptors in developing cerebellar granule neurons. **J Neurosci** 19(24): 10603-10.
- 2. <u>Rumbaugh G</u>, Prybylowski K, Wang JF, Vicini S. (2000) Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. **J Neurophysiology** 83(3): 1300-6.
- 3. Prybylowski K, <u>Rumbaugh G</u>, Wolfe BB, Vicini S. (2000) Increased exon 5 expression alters extrasynaptic NMDA receptors in cerebellar neurons. J **Neurochem** 75(3): 1140-6.
- 4. Ceccon M, <u>Rumbaugh G</u>, Vicini S. (2001) Distinct effect of pregnenolone sulfate on NMDA receptor subtypes. **Neuropharmacology** 40(4): 491-500.
- 5. Vicini S, <u>Rumbaugh G</u>. (2000) A slow NMDA channel: in search of a role. **J Physiology** 525 Pt. 2:283.
- 6. Lee HK, Takamiya K, Han JS, Man H, Kim CH, <u>Rumbaugh G</u>, Yu S, Ding L, He C, Petralia RS, Wenthold RJ, Gallagher M, Huganir RL. (2003) Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. **Cell** 112(5): 631-43.
- <u>Rumbaugh G</u>, Sia GM, Garner CC, Huganir RL. (2003) Synapse-associated protein-97 isoform-specific regulation of surface AMPA receptors and synaptic function in cultured neurons. J Neurosci 23(11): 4567-76.
- <u>Rumbaugh G\*</u>, Tao YX\*, Wang GD\*, Petralia RS, Zhao C, Kauer FW, Tao F, Zhuo M, Wenthold RJ, Raja SN, Huganir RL, Bredt DS, Johns RA. (2003) Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J Neurosci 23(17): 6703-12. (\*Co-First Author)
- 9. Landree LE, Hanlon AL, Strong DW, <u>Rumbaugh G</u>, Miller IM, Thupari JN, Connolly EC, Huganir RL, Richardson C, Witters LA, Kuhajda FP, Ronnett GV. (2004) C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. **J Biol Chem** 279(5): 3817-27.
- 10. Rumbaugh G. (2005) Synapses fight for Glutamate Receptor 1. J Neurosci 25(38): 8347-8348.
- 11. Hayashi T, <u>Rumbaugh G</u>, Huganir RL. (2005) Differential regulation of AMPA receptor subunit trafficking by palmitoylation of two distinct sites. **Neuron** 47(5): 709-723.
- 12. Thomas GM, <u>Rumbaugh G</u>, Harrar DB, Huganir RL. (2005) RSK2 interacts with and phosphorylates PDZ domain-containing proteins and regulates AMPA-R transmission. **Proc Nat'l Acad Sci.** 102(42): 15006-11.
- 13. <u>Rumbaugh G</u>, Adams JP, Kim JH, Huganir RL. (2006) SynGAP regulates synaptic strength and mitogenactivated protein kinases in cultured neurons. **Proc Nat'l Acad Sci.** 21; 103(12): 4344-51
- 14. Shepherd JS\*, <u>Rumbaugh G<sup>\*</sup></u>, Chowdhury A, Huganir RL, Worley P. (2006) Arc regulates homeostatic

synaptic scaling of AMPA receptors in cultured neurons. **Neuron**. 52(3): 475-484. **\*Co-First Author** 

- Sia GM, Beique JC, <u>Rumbaugh G</u>, Cho R, Worley PF, Huganir RL. (2007) Interaction of the N-Terminal Domain of the AMPA Receptor GluR4 Subunit with the Neuronal Pentraxin NP1 Mediates GluR4 Synaptic Recruitment. **Neuron**. 55(1): 87-102.
- 16. Wu Y, Arai AC, <u>Rumbaugh G</u>, Srivastava AK, Turner G, Hayashi T, Suzuki E, Jiang Y, Zhang L, Rodriguez J, Boyle J, Tarpey P, Raymond FL, Nevelsteen J, Froyen G, Stratton M, Futreal A, Gecz J, Stevenson R,

Schwartz CE, Valle D, Huganir RL, Wang T. (2007) Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans. **Proc Nat'l Acad Sci**. 104(46): 18163-18168

- 17. Heine M, Groc L, Frischknecht R, Béïque JC, Lounis B, <u>Rumbaugh G</u>, Huganir RL, Cognet L, Choquet D (2008) Surface Mobility of Postsynaptic AMPARs Tunes Synaptic Transmission. **Science**. 320 (1): 201 205.
- Guo X, Hamilton PJ, Reish NJ, Sweatt JD, Miller CA, <u>Rumbaugh G</u> (2009) Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of schizophrenia. **Neuropsychopharmacology**. 34: 1659-1672.
- Funk AJ, <u>Rumbaugh G</u>, Harotunian V, McCullumsmith RE, Meador-Woodruff JH (2009) Decreased Expression of NMDA Receptor Associated Proteins in Frontal Cortex of Elderly Patients with Schizophrenia. Neuroreport. 20(11): 1019-22.
- Kilgore M, Miller CA, Haggarty SJ, Sweatt JD, <u>Rumbaugh G</u>. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. **Neuropsychopharmacology**. 35: 870-880.
- 21. Miller CA, Gavin CF, White JA, Parrish RR, Honasoge A, Yancey CR, Rivera IM, Rubio MD, <u>Rumbaugh G</u>, Sweatt JD (2010) Cortical DNA methylation maintains remote memory. **Nat Neurosci**. 13(6): 664-6.
- Rex CS, Gavin CF, Rubio MD, Kramar EA, Chen LY, Jia Y, Huganir RL, Muzyczka N, Gall CM, Miller CA, Lynch G, <u>Rumbaugh G</u> (2010) Myosin IIb regulates actin dynamics during synaptic plasticity and memory formation. **Neuron**, 67(4): 603-617
- 23. Rubio MD, Johnson RC, Miller CA, Huganir RL, <u>Rumbaugh G</u> (2011) Regulation of synapse structure and function by distinct Myosin II motors. **J Neurosci**. 31(4): 1448-60.
- 24. Rumbaugh G, Miller CA. (2011) Epigenetic changes in the brain: measuring global histone modifications. Methods Mol Biol. 2011; 670:263-74
- 25. Gavin CF, Rubio MD, Young E, Miller CA, <u>Rumbaugh G</u>. (2011) Myosin II motor activity in the lateral amygdala is required for fear memory consolidation. **Learn Mem**. Dec 14; 19(1): 9-14. doi: 10.1101/lm.024042.111. Print 2012 Jan.
- 26. Kramár EA, Babayan AH, Gavin CF, Cox CD, Jafari M, Gall CM, <u>Rumbaugh G</u>\*, Lynch G\* (2012) Synaptic Evidence for the Efficacy of Spaced Learning. Proc Nat'l Acad Sci. Mar 27;109(13):5121-6. (Co-corresponding author)
- Clement JP, Aceti M, Creson TK, Shi Y, Reish NJ, Almonte AG, Miller B, Miller CA, Wiltgen BJ, Xu X, <u>Rumbaugh G\*</u> (2012) Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. **Cell**. 151(4):709-23.
- 28. Almonte AG, Qadri LH, Sultan FA, Watson JA, Mount DJ, <u>Rumbaugh G</u>, Sweatt JD (2013) Proteaseactivated receptor-1 modulates hippocampal memory formation and synaptic plasticity. **J Neurochem.** Jan;124(1):109-22.
- 29. Griggs EM, Young EJ, <u>Rumbaugh G</u>, Miller CA (2013) MicroRNA-182 Regulates Amygdala-Dependent Memory Formation. **J Neurosci**. 33(4):1734-40.
- 30. Lynch G, Kramár EA, Babayan AH, <u>Rumbaugh G</u>, Gall CM. (2013) Differences between synaptic plasticity thresholds result in new timing rules for maximizing long-term potentiation. **Neuropharmacology.** Jan;64:27-36.
- 31. Clement JP, Ozkan ED, Miller CA, <u>Rumbaugh G</u> (2013) SYNGAP1 links the maturation rate of excitatory synapses to the duration of critical period synaptic plasticity. **J Neurosci.** 33(25): 10447-52
- 32. Young EJ, Griggs EM, Aceti M, Fuchs RA, Zigmond Z, <u>Rumbaugh G</u>, Miller CA (2014) Maintenance Phase Factin Dynamics Enable Persistent Disruption of Methamphetamine-Associated Memory. Biological Psychiatry. In Press Young EJ, Aceti M, Griggs EM, Fuchs RA, Zigmond Z, Rumbaugh G, Miller CA (2014) Selective, Retrieval-Independent Disruption of Methamphetamine-Associated Memory by Actin Depolymerization. **Biol Psychiatry.** 75(2):96-104.

- 33. Ozkan ED, Creson TK, Kramar EA, Rojas CS, Shi Y, Lucero R, Xu X, Noebels JL, Miller CA, Lynch GS, <u>Rumbaugh G</u> (2014) Reduced cognition in Syngap1 mutants is caused by isolated damage within developing forebrain excitatory neurons. **Neuron.** 82(6):1317-33.
- 34. Aguilar-Valles A, Vaissière T, Griggs EM, Mikaelsson MA, Takács IF, Young EJ, <u>Rumbaugh G</u>, Miller CA (2014) Methamphetamine-Associated Memory Is Regulated by a Writer and an Eraser of Permissive Histone Methylation. **Biol Psychiatry.** 76(1):57-65
- Aceti M, Creson TK, Vaissiere T, Rojas C, Huang WC, Wang YX, Petralia RS, Page DT, Miller CA, <u>Rumbaugh G</u> (2015) *Syngap1* Haploinsufficiency Damages a Postnatal Critical period of Pyramidal Cell Structural Maturation Linked to Cortical Circuit Assembly. **Biol Psychiatry.** May 1;77(9):805-15. doi: 10.1016/j.biopsych.2014.08.001. Epub 2014 Aug 13.
- 36. Zhou M, Ottenberg G, Sferrazza GF, Hubbs C, Fallahi M, <u>Rumbaugh G</u>, Brantley A, Lasmézas CI (2015) Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. **Brain**. Apr;138(Pt 4):992-1008. doi: 10.1093/brain/awv002.
- <u>Rumbaugh G</u>, Sillivan SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, \*Miller CA. (2015) Pharmacological Selectivity within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue. **Neuropsychopharmacology**. Apr 3. doi: 10.1038/npp.2015.93. [Epub ahead of print]; [\*Corresponding Author]
- Ozkan ED, Aceti M, Creson TK, Rojas CS, Hubbs C, McGuire MN, Kakad PP, Miller CA, <u>Rumbaugh G</u> (2015) Input-specific regulation of hippocampal circuit maturation by non-muscle Myosin IIB. J Neurochem. Aug;134(3):429-44. doi: 10.1111/jnc.13146. Epub 2015 May 29.
- Young EJ, Blouin A, Briggs SB, Sillivan SE, <u>Rumbaugh G</u>, Miller CA (2016) Nonmuscle myosin IIB as a therapeutic target for the prevention of substance use relapse. **Mol Psychiatry.** May;21(5):615-23. doi: 10.1038/mp.2015.103.
- 40. Ogden KK, Ozkan ED, <u>Rumbaugh G</u> (2016) Prioritizing the development of mouse models for childhood brain disorders. **Neuropharmacology.** Jan;100:2-16. doi: 10.1016/j.neuropharm.2015.07.029.
- Young EJ, Briggs SB, <u>Rumbaugh G</u>, Miller CA (2017) Nonmuscle myosin II inhibition disrupts methamphetamine-associated memory in females and adolescents. **Neurobiol Learn Mem.** 2017 Mar;139:109-116. doi: 10.1016/j.nlm.2017.01.001. Epub 2017 Jan 7.
- Briggs SB, Blouin AM, Young EJ, <u>Rumbaugh G</u>, Miller CA (2017) Memory disrupting effects of nonmuscle myosin II inhibition depend on the class of abused drug and brain region. Learn Mem. 2017 Jan 17;24(2):70-75. doi: 10.1101/lm.043976.116. Print 2017 Feb.
- Wang W., Y. Jia., D.T. Pham, L.C. Palmer, K.-M. Jung, C.D. Cox, <u>G. Rumbaugh</u>, D. Piomelli, C.M. Gall\*, and G. Lynch\* (2017) Atypical endocannabinoid signalling initiates a new form of memory-related plasticity at a cortical input to hippocampus. **Cereb Cortex.** May 17:1-14. doi: 10.1093/cercor/bhx126.
- 44. Sillivan SE, Joseph NF, Jamieson S, King ML, Chévere-Torres I, Fuentes I, Shumyatsky GP, Brantley AF, <u>Rumbaugh G</u>, Miller CA (2017) Susceptibility and Resilience to Posttraumatic Stress Disorder-like Behaviors in Inbred Mice. **Biol Psychiatry.** Dec 15;82(12):924-933. doi: 10.1016/j.biopsych.2017.06.030.
- 45. Fürth D, Vaissière T, Tzortzi O, Xuan Y, Märtin A, Lazaridis I, Spigolon G, Fisone G, Tomer R, Deisseroth K, Carlén M, Miller CA, <u>Rumbaugh G</u>, Meletis K (2018) An interactive framework for whole-brain maps at cellular resolution. **Nat Neurosci**. Jan;21(1):139-149. doi: 10.1038/s41593-017-0027-7.
- Weldon M, Kilinc M, Lloyd Holder J Jr, <u>Rumbaugh G</u> (2018) The first international conference on SYNGAP1related brain disorders: a stakeholder meeting of families, researchers, clinicians, and regulators. J Neurodev Disord. 2018 Feb 5;10(1):6. doi: 10.1186/s11689-018-9225-1.
- Kilinc M, Creson T, Rojas C, Aceti M, Ellegood J, Vaissiere T, Lerch JP, <u>Rumbaugh G</u>. (2018) Speciesconserved SYNGAP1 phenotypes associated with neurodevelopmental disorders. **Mol Cell Neurosci.** Mar 24. pii: S1044-7431(18)30030-7. doi: 10.1016/j.mcn.2018.03.008. [Epub ahead of print]
- 48. Spicer TP, Hubbs C, Vaissiere T, Collia D, Rojas C, Kilinc M, Vick K, Madoux F, Baillargeon P, Shumate J, Martemyanov KA, Page DT, Puthanveettil S, Hodder P, Davis R, Miller CA, Scampavia L, <u>Rumbaugh G</u>

(2018) Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders. **Mol Neuropsychiatry.** Feb;3(3):141-150. doi: 10.1159/000481731.

- 49. Blouin AM, Pisupati S, Hoffer CG, Hafenbreidel M, Jamieson SE, <u>Rumbaugh G</u>, Miller CA (2018) Social stress-potentiated methamphetamine seeking. **Addict Biol.** 2018 Aug 14. doi: 10.1111/adb.12666. [Epub ahead of print]
- Briggs SB, Hafenbreidel M, Young EJ, <u>Rumbaugh G</u>, Miller CA (2018) The role of nonmuscle myosin II in polydrug memories and memory reconsolidation. Learn Mem. 2018 Aug 16;25(9):391-398. doi: 10.1101/lm.046763.117.
- 51. Michaelson SD, Ozkan ED, Aceti M, Maity S, Llamosas N, Weldon M, Mizrachi E, Vaissiere T, Gaffield MA, Christie JM, Holder JL, Miller CA, <u>Rumbaugh G</u> (2018) *SYNGAP1* Heterozygosity Disrupts Sensory Processing by Reducing Touch-Related Activity within Somatosensory Cortex Circuits. **Nat Neurosci.** 2018 Dec;21(12):1-13. doi: 10.1038/s41593-018-0268-0. Epub 2018 Nov 21.
- 52. Sillivan SE, Jones ME, Jamieson S, <u>Rumbaugh G</u>, Miller CA (2019) Bioinformatic analysis of long-lasting transcriptional and translational changes in the basolateral amygdala following acute stress. **PLoS One**. 2019 Jan 10;14(1):e0209846. doi: 10.1371/journal.pone.0209846.
- 53. Sillivan S, , Geuze E, Vermetten E, Vinkers C, Ressler K, Rutten B, de Nijs L, Klenge TI, Boks M, Kleinjans J, Jamieson S, Jones M, Krauskopf J, Snijders C, Joseph N, Berretta S, <u>Rumbaugh G</u>, Miller CA (2019) microRNA regulation of persistent stress-enhanced memory. **Molecular Psychiatry**. May 29. doi: 10.1038/s41380-019-0432-2.
- 54. Sridharan B; Hubbs C; Llamosas N; Kilinc M; Singhera FU; Willems E; Piper DR; Scampavia L; <u>Rumbaugh G\*</u>, Spicer TP \* (2019) A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons. **Sci Rep** Jun 21;9(1):9000. doi: 10.1038/s41598-019-45265-1. (*\*Co-communicating authors*)
- Creson TK, Rojas C, Hwaun E, Vaissiere T, Kilinc M, Jimenez-Gomez A, Holder JL, Tang J, Colgin LL, Miller CA, <u>Rumbaugh G</u> (2019) Re-expression of SynGAP Protein in Adulthood Improves Translatable Measures of Brain Function and Behavior. **Elife.** Apr 26;8. pii: e46752. doi: 10.7554/eLife.46752.
- Jones ME, Sillivan SE, Jamieson S, <u>Rumbaugh G</u>, Miller CA (2019) microRNA mir-598-3p mediates susceptibility to stress enhancement of remote fear memory. Learn Mem. 2019 Aug 15;26(9):363-372. doi: 10.1101/lm.048827.118. Print 2019 Sep.
- Radnai L, Stremel RF, Sellers JR, <u>Rumbaugh G</u>, Miller CA (2019) A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors. J Vis Exp. Aug 17;(150). doi: 10.3791/60017.

## 3. PATENTS AND PATENT APPLICATIONS

Miller C, Griffin P, Kamenecka T, Rumbaugh G, Surman M, Young S, Duddy S, Radnai L; "Nonmuscle myosin II inhibitors for Substance Use Relapse" 62/685,158, June 14, 2018

#### **CURRENT GRANT SUPPORT**

Causal Interactions between genetic risk, precise cortical connectivity, and autism-associated behaviors.The goal of this project is to determine how a major neurodevelopmental disorder risk factor in mice regulates the circuits driving active touch.09/01/2012-04/30/2023R01MH096847Rumbaugh (PD/PI); Miller and Christie (MPIs)09/01/2012-04/30/2023Circuit-level substrates of ASD-related cognitive and behavioral impairments09/01/2012-04/30/2023This grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.12/15/2019-11/30/2024R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMiller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMiller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMiller (PD/PI); Rumbaugh (MPI)04/01/2015-01/31/2020NIH/NIMARumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHRumbaugh (PI)04/01/2015-01/31/2020	R01NS110307	Rumbaugh (PI)	12/01/2019-11/30/2024					
The goal of this project is to determine how a major neurodevelopmental disorder risk factor in mice regulates the circuits driving active touch.    09/01/2012-04/30/2023      R01MH096847    Rumbaugh (PD/PI); Miller and O9/01/2012-04/30/2023    09/01/2012-04/30/2023      NIH/NIMH    Christie (MPIs)    09/01/2012-04/30/2023      Circuit-level substrates of ASD-related cognitive and behavioral impairments    09/01/2012-04/30/2023      This grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.    12/15/2019-11/30/2024      R01DA049544    Miller (PD/PI); Rumbaugh (MPI)    12/15/2019-11/30/2024      NIH/NIDA    Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory.    11      Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory.    04/01/2015-01/31/2020      R01MH108408    Rumbaugh (PI)    04/01/2015-01/31/2020      NIH/NIMH    Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.    The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	NIH/NINDS							
regulates the circuits driving active touch.R01MH096847Rumbaugh (PD/PI); Miller and Christie (MPIs)09/01/2012-04/30/2023NIH/NIMHChristie (MPIs)Circuit-level substrates of ASD-related cognitive and behavioral impairments09/01/2012-04/30/2023This grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.12/15/2019-11/30/2024R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.12 (15/2019-11/30/2024R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.The goal of this project is to develop biomarkers of cognitive nutant mice and then test the efficacy of Ras/ERK pathway	Causal Interactions between genetic risk, precise cortical connectivity, and autism-associated behaviors.							
R01MH096847Rumbaugh (PD/PI); Miller and Christie (MPIs)09/01/2012-04/30/2023NIH/NIMHChristie (MPIs)Circuit-level substrates of ASD-related cognitive and behavioral impairmentsThis grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.The goal of this syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	The goal of this project is to determine how a major neurodevelopmental disorder risk factor in mice							
NIH/NIMHChristie (MPIs)Circuit-level substrates of ASD-related cognitive and behavioral impairmentsThis grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	regulates the circuits driving active touch.							
NIH/NIMHChristie (MPIs)Circuit-level substrates of ASD-related cognitive and behavioral impairmentsThis grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway								
Circuit-level substrates of ASD-related cognitive and behavioral impairments      This grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.      R01DA049544    Miller (PD/PI); Rumbaugh (MPI)    12/15/2019-11/30/2024      NIH/NIDA    Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory.      The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.      R01MH108408    Rumbaugh (PI)    04/01/2015-01/31/2020      NIH/NIMH    Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.    The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway		• • • •	09/01/2012-04/30/2023					
This grant was awarded to understand how sensory impairments common in neurodevelopmental disorders contribute to cognitive and behavioral abnormalities.      R01DA049544    Miller (PD/PI); Rumbaugh (MPI)    12/15/2019-11/30/2024      NIH/NIDA    Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory.      The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.    04/01/2015-01/31/2020      R01MH108408    Rumbaugh (PI)    04/01/2015-01/31/2020      NIH/NIMH    Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	-							
disorders contribute to cognitive and behavioral abnormalities. <b>R01DA049544</b> <i>Miller (PD/PI);</i> <b>Rumbaugh (MPI)</b> 12/15/2019-11/30/2024 <b>NIH/NIDA</b> <i>Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- <u>associated memory.</u> The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders. <b>R01MH108408 Rumbaugh (PI)</b> 04/01/2015-01/31/2020 <b>NIH/NIMH</b> <u>Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway</u></i>	Circuit-level substrates of ASD-related cognitive and behavioral impairments							
R01DA049544Miller (PD/PI); Rumbaugh (MPI)12/15/2019-11/30/2024NIH/NIDAMyosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory. The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	This grant was awarded to understand how sensory impairments common in neurodevelopmental							
NIH/NIDA      Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.      The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.      R01MH108408    Rumbaugh (PI)      04/01/2015-01/31/2020      NIH/NIMH      Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	disorders contribute to	cognitive and behavioral abnormalities.						
NIH/NIDA      Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.      The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.      R01MH108408    Rumbaugh (PI)      04/01/2015-01/31/2020      NIH/NIMH      Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway								
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid- associated memory.associated memory.The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders. <b>R01MH108408Rumbaugh (PI)</b> 04/01/2015-01/31/2020 <b>NIH/NIMH</b> Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	R01DA049544	Miller (PD/PI); Rumbaugh (MPI)	12/15/2019-11/30/2024					
associated memory.The goal of this project is to define the role of myosin II in the brain, to better understand its potential as a therapeutic target in memory disorders.R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	NIH/NIDA							
understand its potential as a therapeutic target in memory disorders.       R01MH108408    Rumbaugh (PI)    04/01/2015-01/31/2020      NIH/NIMH    Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-							
R01MH108408Rumbaugh (PI)04/01/2015-01/31/2020NIH/NIMHEvaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in Syngap1 mutant mice and then test the efficacy of Ras/ERK pathway	associated memory. The goal of this project is to define the role of myosin II in the brain, to better							
<b>NIH/NIMH</b> <u>Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.</u> The goal of this project is to develop biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway	understand its potential as a therapeutic target in memory disorders.							
<b>NIH/NIMH</b> <u>Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and their application in efficacy testing of Ras pathway inhibitors.</u> The goal of this project is to develop biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway			04/04/2045 04/24/2020					
<u>Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and</u> <u>their application in efficacy testing of Ras pathway inhibitors.</u> The goal of this project is to develop biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway		Rumbaugh (PI)	04/01/2015-01/31/2020					
their application in efficacy testing of Ras pathway inhibitors. The goal of this project is to develop biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway	•							
biomarkers of cognitive ability in <i>Syngap1</i> mutant mice and then test the efficacy of Ras/ERK pathway	Evaluation of novel biomarkers of cognition in a model of sporadic developmental brain disorders and							
inhibitors using these optimized measures.								
	inhibitors using these of	ptimized measures.						
<b>1R01MH113648</b> Rumbaugh(PD/PI); Scampavia and Spicer(MPIs) 07/01/2017-03/31/2020	1R01MH113648	Rumbaugh(PD/PI): Scampavia and Spicer(MPIs)	) 07/01/2017-03/31/2020					
	NIH/NIMH							
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that								
<u>Restore Protein Expression Caused by Genetic Haploinsufficiency.</u> The goal of this project is to test the								

<u>Restore Protein Expression Caused by Genetic Haploinsufficiency.</u> The goal of this project is to test the limits of scalability of HTS-compatible assays built from primary neurons. We will optimize scalability using a HTS-compatible assay for *Syngap1* expression in mouse primary neurons.